Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate

去势抵抗性前列腺男性临床结果的预后模型

基本信息

  • 批准号:
    8681186
  • 负责人:
  • 金额:
    $ 23.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-06 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The dilemma in treating men with castration resistant prostate cancer (CRPC) lies not only in the heterogeneity of the disease but also the spectrum of patients that have the disease. Considerable energy has been dedicated to understanding tumor heterogeneity and developing prognostic models of clinical outcomes in men with CRPC who are chemotherapy naive. The identification of prognostic factors of clinical outcomes in men with CRPC who failed frontline chemotherapy has not, however, been investigated. Such identification is increasingly important due to the large number of patients who not only fail frontline chemotherapy but have excessive toxicity due to docetaxel. We anticipate that the same patient may need different models (prognostic calculators) at different stages of their care pathway as more prognostic information on that person's condition accumulates. The specific aims in this proposal are: 1) to develop a prognostic model that will predict overall survival (OS) in men with CRPC who failed first line chemotherapy. The model will be validated for predictive accuracy using an independent dataset. 2) To develop a prognostic model that will predict progression-free survival (PFS) in CRPC men who failed first line chemotherapy. The model will be validated for predictive accuracy using an independent dataset. 3a) To determine if e 30% decline in prostate specific antigen (PSA) at 3-months following treatment with cabazitaxel, the only FDA approved drug for treating men who failed frontline chemotherapy, is a valid surrogate marker of OS. 3b) to develop and validate a prognostic model that will predict post-therapy decline in PSA (e30% decline from baseline at 3-months). 4) To test for the dependence between time to progression and OS using the TROPIC trial. Innovation: This study has a high degree of innovation because of its strong potential to positively impact the design and conduct of future trials in PC. In particular, this study will be the first to identify and validate models of clinical outcomes and will incorporate data from the two largest phase III trials of men with advanced CRPC who failed frontline chemotherapy. These models are completely absent for the growing group of men who have received frontline chemotherapy and are considering secondary chemotherapy. The development of these models will facilitate discussions with CRPC patients, as well as help integrate these models into the design, conduct and analysis of new clinical trials in PC and patient care.
描述(由申请人提供):治疗去势抵抗性前列腺癌(CRPC)的困境不仅在于疾病的异质性,而且在于患者的谱系。大量的精力已经投入到了解肿瘤异质性和发展临床预后模型的男性CRPC谁是化疗初期。然而,尚未对一线化疗失败的CRPC患者临床结果的预后因素进行研究。由于大量患者不仅一线化疗失败,而且由于多西紫杉醇的过度毒性,这种识别变得越来越重要。我们预计,随着更多关于患者病情的预后信息的积累,同一患者在其护理途径的不同阶段可能需要不同的模型(预后计算器)。本提案的具体目的是:1)建立一种预测一线化疗失败的CRPC患者总生存期(OS)的预后模型。该模型将使用独立数据集验证预测准确性。2)建立一种预测一线化疗失败的CRPC患者无进展生存期(PFS)的预后模型。该模型将使用独立数据集验证预测准确性。3a)确定卡巴他赛治疗3个月后前列腺特异性抗原(PSA)下降30%是否为OS的有效替代标志物,卡巴他赛是FDA批准的唯一用于治疗一线化疗失败的男性的药物。3b)开发并验证一种预测治疗后PSA下降的预后模型(3个月时PSA较基线下降30%)。4)使用TROPIC试验检验进展时间与OS之间的相关性。创新:本研究具有高度的创新,因为它对未来PC试验的设计和实施具有积极影响的强大潜力。特别是,这项研究将是第一个确定和验证临床结果模型的研究,并将纳入两项最大的晚期CRPC患者一线化疗失败的III期试验的数据。对于越来越多接受过一线化疗并正在考虑二次化疗的男性来说,这些模型完全不存在。这些模型的发展将促进与CRPC患者的讨论,并有助于将这些模型整合到PC和患者护理的新临床试验的设计、实施和分析中。

项目成果

期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints.
调整中间终点和主要终点临床试验监测的 I 类错误率。
On model specification and selection of the Cox proportional hazards model.
  • DOI:
    10.1002/sim.5876
  • 发表时间:
    2013-11-20
  • 期刊:
  • 影响因子:
    2
  • 作者:
    Lin, Chen-Yen;Halabi, Susan
  • 通讯作者:
    Halabi, Susan
A Simple Method for Deriving the Confidence Regions for the Penalized Cox's Model via the Minimand Perturbation.
Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome.
以事件发生时间为结果时,在完全随机因子设计中测试主要效应和相互作用的样本量要求和研究持续时间。
On the use of min-max combination of biomarkers to maximize the partial area under the ROC curve.
关于使用生物标志物的最小-最大组合来最大化 ROC 曲线下的部分面积。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUSAN HALABI其他文献

SUSAN HALABI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUSAN HALABI', 18)}}的其他基金

Sieve based full likelihood approach for the Cox proportional hazards model with applications to immunotherapies trials
基于筛法的 Cox 比例风险模型的完全似然法及其在免疫治疗试验中的应用
  • 批准号:
    10577723
  • 财政年份:
    2023
  • 资助金额:
    $ 23.16万
  • 项目类别:
Research Triangle Center of Excellence in Regulatory Science and Innovation
监管科学与创新卓越研究三角中心
  • 批准号:
    10756714
  • 财政年份:
    2023
  • 资助金额:
    $ 23.16万
  • 项目类别:
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer
雄激素产生、摄取和代谢的相互作用对去势抵抗性前列腺癌预后的影响
  • 批准号:
    10460400
  • 财政年份:
    2021
  • 资助金额:
    $ 23.16万
  • 项目类别:
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer
雄激素产生、摄取和代谢的相互作用对去势抵抗性前列腺癌预后的影响
  • 批准号:
    10908110
  • 财政年份:
    2021
  • 资助金额:
    $ 23.16万
  • 项目类别:
Serum Androgens as Predictors of Survival in Metastatic Prostate Cancer
血清雄激素作为转移性前列腺癌生存的预测因子
  • 批准号:
    8881946
  • 财政年份:
    2015
  • 资助金额:
    $ 23.16万
  • 项目类别:
Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate
去势抵抗性前列腺男性临床结果的预后模型
  • 批准号:
    8298156
  • 财政年份:
    2011
  • 资助金额:
    $ 23.16万
  • 项目类别:
Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate
去势抵抗性前列腺男性临床结果的预后模型
  • 批准号:
    8188071
  • 财政年份:
    2011
  • 资助金额:
    $ 23.16万
  • 项目类别:
Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate
去势抵抗性前列腺男性临床结果的预后模型
  • 批准号:
    8471668
  • 财政年份:
    2011
  • 资助金额:
    $ 23.16万
  • 项目类别:

相似海外基金

Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
研究项目 2 蛋白质基因组引导的乳腺癌患者异种移植转移的治疗靶向
  • 批准号:
    10733315
  • 财政年份:
    2023
  • 资助金额:
    $ 23.16万
  • 项目类别:
SQLE and Sterols Contribute to Racial Disparity in ER+ Breast Cancer Patient Survival
SQLE 和甾醇导致 ER 乳腺癌患者生存率的种族差异
  • 批准号:
    10571020
  • 财政年份:
    2023
  • 资助金额:
    $ 23.16万
  • 项目类别:
Establishing industrial production of components that enable expanding accessibility of PET imaging to cancer patient population.
建立组件的工业化生产,使癌症患者群体能够更容易地获得 PET 成像。
  • 批准号:
    10698218
  • 财政年份:
    2023
  • 资助金额:
    $ 23.16万
  • 项目类别:
Washington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft Models
华盛顿大学 PDX 开发和试验中心 - Abemaciclib 联合 Olaparib 在卵巢癌和乳腺癌患者异种移植模型中的评估
  • 批准号:
    10582164
  • 财政年份:
    2022
  • 资助金额:
    $ 23.16万
  • 项目类别:
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
增强癌症患者在临终时最佳使用抗血栓治疗的能力
  • 批准号:
    10039823
  • 财政年份:
    2022
  • 资助金额:
    $ 23.16万
  • 项目类别:
    EU-Funded
Convening a gynecologic cancer patient advisory group to adapt a digital health tool
召集妇科癌症患者咨询小组以采用数字健康工具
  • 批准号:
    460767
  • 财政年份:
    2022
  • 资助金额:
    $ 23.16万
  • 项目类别:
    Miscellaneous Programs
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
增强癌症患者在临终时最佳使用抗血栓治疗的能力
  • 批准号:
    10038000
  • 财政年份:
    2022
  • 资助金额:
    $ 23.16万
  • 项目类别:
    EU-Funded
Longitudinal mixed method investigation of social networks and affective states as determinants of smoking behavior among cancer patient
社会网络和情感状态作为癌症患者吸烟行为决定因素的纵向混合方法调查
  • 批准号:
    10513670
  • 财政年份:
    2021
  • 资助金额:
    $ 23.16万
  • 项目类别:
Improving the translational value of head and neck cancer patient-in-mouse models
提高头颈癌小鼠模型的转化价值
  • 批准号:
    10598311
  • 财政年份:
    2021
  • 资助金额:
    $ 23.16万
  • 项目类别:
Improving the translational value of head and neck cancer patient-in-mouse models
提高头颈癌小鼠模型的转化价值
  • 批准号:
    10442585
  • 财政年份:
    2021
  • 资助金额:
    $ 23.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了